最新ニュース Surmodics (NASDAQ:SRDX) 株価情報

Surmodics

Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

Surmodics Inc

WIIM

SRDX

Surmodics shares are trading lower. The company reported Q2 financial results and issued FY25 guidance below estimates.

Needham analyst Mike Matson reiterates Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) from Hold to Hold.

News

Reiteration

Analyst Ratings

Needham Reiterates Hold on Surmodicsto Hold

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) is looking for FY2025 GAAP EPS of $(1.60)-$(1.40) vs $(0.61) analyst estimate..

Guidance

Surmodics Sees FY2025 GAAP EPS $(1.60)-$(1.40) vs $(0.61) Est

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) is looking for FY2025 Adj EPS of $(0.62)-$(0.42) vs $(0.37) analyst estimate. sees sales of $114.000 million-$117.000 million vs $127.27 million analyst estimate.

Surmodics Sees FY2025 Adj EPS $(0.62)-$(0.42) vs $(0.37) Est; Sees Sales $114.000M-$117.000M vs $127.27M Est

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 285.71 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $28.09 million which missed the analyst consensus estimate of $32.23 million by 12.86 percent. This is a 12.12 percent decrease over sales of $31.96 million the same period last year.

Earnings

Earnings Misses

Surmodics Q2 Adj. EPS $(0.13) Misses $(0.11) Estimate, Sales $28.09M Miss $32.23M Estimate

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that Surmodics will report an earnings per share (EPS) of $-0.09. 
Investors in Surmodics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.08, leading to a 4.06% drop in the share price on the subsequent day.
Here's a look at Surmodics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.29</td>
<td>-0.33</td>
<td>-0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>-0.13</td>
<td>-0.27</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-0.0%</td>
<td>-0.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745953377_0.png" alt="eps graph" />
<h3>Tracking Surmodics's Stock Performance</h3>
Shares of Surmodics were trading at $31.1 as of April 28. Over the last 52-week period, shares are down 7.53%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Insights on Surmodics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Surmodics.
With 1 analyst ratings, Surmodics has a consensus rating of Buy. The average one-year price target is $43.0, indicating a potential 38.26% upside.
<h3>Peer Ratings Overview</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Treace Medical Concepts, ClearPoint Neuro and Delcath Systems, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Treace Medical Concepts, with an average 1-year price target of $9.17, suggesting a potential 70.51% downside.</li>
<li>Analysts currently favor an Buy trajectory for ClearPoint Neuro, with an average 1-year price target of $25.0, suggesting a potential 19.61% downside.</li>
<li>Analysts currently favor an Buy trajectory for Delcath Systems, with an average 1-year price target of $24.0, suggesting a potential 22.83% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for Treace Medical Concepts, ClearPoint Neuro and Delcath Systems, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surmodics</td>
<td>Buy</td>
<td>-2.06%</td>
<td>$13.56M</td>
<td>-3.17%</td>
</tr>
<tr>
<td>Treace Medical Concepts</td>
<td>Neutral</td>
<td>10.44%</td>
<td>$55.48M</td>
<td>-0.46%</td>
</tr>
<tr>
<td>ClearPoint Neuro</td>
<td>Buy</td>
<td>14.11%</td>
<td>$4.76M</td>
<td>-19.81%</td>
</tr>
<tr>
<td>Delcath Systems</td>
<td>Buy</td>
<td>2701.48%</td>
<td>$12.97M</td>
<td>-8.79%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Surmodics ranks at the bottom for Revenue Growth and Gross Profit, with negative values compared to peers. However, it ranks at the top for Return on Equity, showing a positive performance in this metric. The Consensus rating for Surmodics is in line with one peer and higher than the other two.
<h3>Delving into Surmodics's Background</h3>
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
<h3>Unraveling the Financial Story of Surmodics</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Surmodics's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -2.06%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Surmodics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -12.2%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Surmodics's ROE stands out, surpassing industry averages. With an impressive ROE of -3.17%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.13%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Surmodics's debt-to-equity ratio is below the industry average at 0.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/SRDX/earnings">To track all earnings releases for Surmodics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at Surmodics's Upcoming Earnings Report

Surmodics Reveals Publication Of TRANSCEND Trial, Highlighting Drug-Delivery Technology Of Its SurVeil Drug-Coated Balloon

These past three months were not what U.S. <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">dealmakers wanted or expected</a>.
As of April 3, transaction tracker Dealogic showed zero percent growth in U.S.-based M&amp;A volume compared to last year&#8217;s first quarter.
Elsewhere? Volume is spiking triple digits.
<ul>
<li>The Middle East and Africa combined are seeing 123% growth in M&amp;A.</li>
<li>Japan: 105%</li>
<li>Asia: 103%</li>
</ul>
Deal volume is also up in Canada, Europe and Australia. Only in Latin America is it in the red, with <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/03/44342234/deal-dispatch-trump-ma-boom-is-a-bust-purple-mattress-considers-sale-celtics-auction-heats-up">barely a peep</a> coming from the U.S.
For those keeping track of who correctly predicted this downtrend, don&#8217;t look to Bank of America. After Election Day, the firm&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates">analysts boldly predicted</a> that the then-incoming Trump administration would remove Federal Trade Commission chair Lina Khan and, presto, the antitrust roadblocks for M&amp;A activity would be removed.
Those analysts were wrong. Just 10 days after Trump&#8217;s inauguration, the U.S. Department of Justice <a href="https://www.benzinga.com/news/legal/25/01/43353124/hewlett-packard-enterprise-shares-fall-as-us-department-of-justice-sues-to-block-juniper-acquisition">sued to block</a> Hewlett Packard Enterprise&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) $14 billion deal to acquire networking gear maker Juniper Networks. In March, Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) <a href="https://julian-34159.medium.com/m-a-malaise-whats-behind-the-2025-deal-slowdown-8471a15b914c">saw its stock price fall</a> after the FTC challenged a proposed acquisition by private equity firm GTCR LLC.
Those BofA analysts also forgot that the previous Trump administration was not particularly lenient regarding consolidation. AT&amp;T and Time Warner; Sinclair and Tribune Media; Broadcom and Qualcomm; DraftKings and FanDuel — <a href="https://www.benzinga.com/news/asset-sales/25/03/44202239/deal-dispatch-tiktok-walgreens-raizen">all blocked</a>.
On the shiny side, gold-related M&amp;A deals have increased, but transaction sizes are much smaller, Benzinga&#8217;s Stjepan Kalinic <a href="https://www.benzinga.com/news/legal/25/03/44490949/gold-ma-deals-are-accelerating-but-average-deals-are-smaller-research-shows">wrote this week</a>.
See Also: <a href="https://www.benzinga.com/government/regulations/25/04/44648681/powell-cites-tariff-driven-inflation-risks-shrugs-off-trumps-call-for-perfect-time-to-cut-rates">Trump Urges Immediate Rate Cuts, Powell Says It&#8217;s &#8216;Too Soon&#8217; As Tariffs Will Likely Drive Inflation</a>
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>I Squared Capital is considering selling its European trailer-leasing business, TIP Group, which could be valued at over €3 billion ($3.2 billion). The Miami-based firm is consulting advisers but has not yet launched a formal sale process, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-04-02/i-squared-said-to-weigh-3-billion-sale-of-trailer-leasing-firm?srnd=phx-deals&amp;sref=TBDibEcD">reports</a>. Based in Amsterdam, TIP Group may attract interest from infrastructure funds and industry peers. I Squared acquired the company in 2018 from HNA Group and has since expanded it through acquisitions, including Trailer Wizards in Canada and Eurotrail UK Ltd. The company was rebranded as TIP Group in 2022.</li>
</ul>
<ul>
<li>Bowmark Capital is working with Arma Partners on a potential sale of workforce management software firm Totalmobile, which could be valued at over £500 million ($649 million). A formal sale process may start later this year, according <a href="https://www.bloomberg.com/news/articles/2025-04-02/pe-firm-bowmark-said-to-weigh-500-million-sale-of-totalmobile?sref=TBDibEcD">to</a> Bloomberg. Totalmobile, which provides field service management software, could attract interest from private equity firms and industry players. Bowmark acquired the company in 2020, and deliberations on the sale are still in the early stages.</li>
</ul>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Final bids for Eni SpA&#8216;s 15% stake in Plenitude, a renewables company, are expected in the coming weeks. Apollo Global Management, Ares Management and Stonepeak are among the interested parties, according to Bloomberg—initial interest values Plenitude between €12 billion and €13 billion ($14 billion).</li>
</ul>
<ul>
<li>Ayrmid Ltd. <a href="https://www.benzinga.com/25/03/44564776?57575">offered to acquire</a> Bluebird Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) for an upfront cash payment of $4.50 per share. The company topped a $3.00 per share bid from private equity firms <a href="https://www.benzinga.com/25/02/43880289/bluebird-bio-to-be-acquired-by-carlyle-group-sk-capital-former-mirati-therapeutics-ceo-set-to-lead-post-deal">Carlyle and SK Capital Partners</a>.</li>
</ul>
<ul>
<li>Rocket Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44565671/rocket-acquires-mr-cooper-just-weeks-after-buying-redfin-brings-together-the-homeownership-experience-at-scale">announced it will acquire</a> Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) in an all-stock transaction for $9.4 billion in equity value. The move comes just after Rocket's $1.75 billion acquisition of <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44237879/rocket-redfin-deal-aims-to-create-end-to-end-real-estate-solution-where-does-that-leave-zillow">online real estate broker Redfin Corp. </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDFN#NASDAQ">RDFN</a>).&nbsp;</li>
</ul>
<ul>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) <a href="https://www.benzinga.com/25/04/44643347/hershey-expands-snack-empire-with-acquisition-of-lesserevil-for-750m">agreed to acquire</a> snack brand LesserEvil. This move reflects the confectionery giant&#8217;s ongoing effort to expand from sweets such as Reese&#8217;s and Jolly Ranchers into the better-for-you snack sector. The acquisition is <a href="https://www.wsj.com/business/deals/hershey-nears-750-million-deal-for-lesserevil-popcorn-brand-4ca3d468?mod=lead_feature_below_a_pos1" target="_blank" rel="noreferrer noopener">reportedly</a> valued at around $750 million.</li>
</ul>
<ul>
<li>Rogers Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCI#NYSE">RCI</a>) said on Friday it agreed to receive a 7 billion Canadian dollar (~$5 billion) equity investment from funds managed by Blackstone Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), supported by <a href="https://www.benzinga.com/news/asset-sales/25/04/44646240/rogers-scores-5-billion-blackstone-deal-to-cut-debt-unlock-wireless-infrastructure-value">several Canadian institutional investors</a>.</li>
</ul>
<ul>
<li>President Trump confirmed that the U.S. is <a href="https://in.benzinga.com/general/social-media/25/02/43511395/trump-pushes-for-tiktok-deal-china-could-oblige-if-it-werent-for-those-tariffs-heres-what-we-know" target="_blank" rel="noreferrer noopener">nearing a deal</a> to spare TikTok from a potential ban, with ongoing discussions involving multiple investors and a possible tariff agreement with China. During <a href="https://www.benzinga.com/25/04/44641024/trump-says-us-close-to-tiktok-deal-reiterates-his-offer-of-tariff-relief-to-secure-chinas-consent-the-tariffs-give-us-great-power-to-negotiate">remarks aboard</a> Air Force One, Trump didn&#8217;t specify whether the &#8220;very good group of people&#8221; interested in TikTok includes OnlyFans founder Tim Stokely. AppLovin and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44645102/applovin-wants-tiktok-but-can-it-beat-amazon-and-onlyfans-to-the-punch">also reportedly interested</a>.</li>
</ul>
<h2 class="wp-block-heading">Bankruptcy Block</h2>
<ul>
<li>Hooters, the restaurant chain known for its all-female waitstaff and neon orange branding, <a href="https://www.benzinga.com/personal-finance/25/04/44647084/hooters-files-for-bankruptcy-says-brand-isnt-going-anywhere">officially filed for bankruptcy protection</a>. The Chapter 11 filing allows the chain to continue normal operations during the proceeding. Hooters said that all of its 100 restaurants will be sold to two existing franchisees, which own and operate more than 30% of Hooters&#8217; locations in the U.S.</li>
</ul>
For the previous edition of <a href="https://www.benzinga.com/news/25/03/44546940/deal-dispatch-bezos-backed-crop-company-wilts-tech-startup-nabs-napster-for-207-million">Deal Dispatch, click here</a>.

Politics

AMZN

BLUE

COOP

RDFN

SHEL

Deal Dispatch: US M&A Is Quiet, But Abroad? Volume Is Spiking

Biotech

Health Care

General

Surmodics Announced The Commercial Release Of The Pounce XL Thrombectomy System, The Latest In A Suite Of Pounce Thrombectomy Systems That Provide Rapid Endovascular Removal Of Acute Or Chronic Clot From Peripheral Arteries

Lake Street analyst Brooks O'Neil upgrades Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) from Hold to Buy and maintains the price target from $43 to $43.

Upgrades

Price Target

Lake Street Upgrades Surmodics to Buy, Maintains Price Target to $43

<h2 class="wp-block-heading">New On The Block</h2>
Raizen, a Brazilian joint venture between Shell plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) and Cosan SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSAN#NYSE">CSAN</a>), tapped JPMorgan to shop around its Argentinian oil refinery and gas stations network. Bloomberg recently <a href="https://www.bloomberg.com/news/articles/2025-03-06/raizen-is-said-to-hire-jpmorgan-for-argentina-energy-assets-sale?srnd=phx-deals">reported</a> that the company is undergoing a "profound" portfolio revision, citing CEO Nelson Gomes&#8216;s comments to analysts during an earnings call.
<h2 class="wp-block-heading">Updates From The Block</h2>
Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) may be heading to the private sector, thanks to a $10 billion deal with Sycamore Partners. The transaction, approved by Walgreens&#8217; board, offers shareholders $11.45 per share in cash. Gary Black of The Future Fund LLC shared the news on social media, quipping, "I've talked before about how this company shouldn't be public." And who's pulling the strings? Executive chairman Stefano Pessina, who owns a 16.9% stake and clearly decided it was time to take his pharmacy empire <a href="https://www.benzinga.com/markets/equities/25/03/44185847/gary-black-says-walgreens-is-a-company-that-shouldnt-be-public-cites-largest-shareholders-role-in-10-billion-sycamore-deal">out of the public eye</a>.
President Donald Trump wants a U.S. sovereign wealth fund to buy TikTok&#8216;s U.S. business. That&#8217;s a bit like suggesting that a college student who is knee-deep in loans save up for a private jet. U.S. debt is exorbitant and the Trump administration is (they say) <a href="https://www.benzinga.com/news/25/03/44143475/trumps-u-s-doge-service-claims-65b-in-savings-experts-call-it-smoke-and-mirrors-amid-resignations">focused on reducing it</a>. However, <a href="https://www.reuters.com/markets/wealth/dealmaker-michael-grimes-expected-lead-new-us-sovereign-wealth-fund-sources-say-2025-03-05/?utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=newsletter_axiosprorata&amp;stream=top">Reuters</a> is reporting that Morgan Stanley&#8216;s Michael Grimes, who helped steer the Uber IPO and the Twitter takeover, is overseeing the formation of a sovereign wealth fund for Uncle Sam. But with TikTok&#8217;s April 5 deadline looming, time is of the essence. Tick tock. Pun intended.
Sure, a deal could get signed by then, but each passing day makes it feel more like a Hail Mary pass—except this time, instead of catching a football, the U.S. is hoping to catch a lip-syncing, trendsetting social media giant.
Meanwhile, Onsemi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) upped its bid for Allegro MicroSystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) to acquire the company for $35.10 per share, valuing the deal at $6.9 billion. This represents an increase over an initial $34.50 per share proposal submitted on Sept. 2.
<h2 class="wp-block-heading">Off The Block</h2>
American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) agreed to acquire Bellevue, Wash.-based Center, according to <a href="https://www.bloomberg.com/news/articles/2025-03-06/american-express-to-acquire-expense-management-company-center?srnd=phx-deals">Bloomberg</a>. Center is a software provider backed by Durable Capital Partners, Top Tier Capital Partners and Mango Capital.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Canoo, the electric vehicle startup that never quite got rolling, is getting a reboot—from its own CEO, no less. Anthony Aquila is buying nearly all of Canoo's assets out of bankruptcy for $4 million in cash, per <a href="https://techcrunch.com/2025/03/05/canoos-ceo-is-buying-the-bankrupt-ev-startups-assets/">TechCrunch</a>. The sale is expected to erase the $11 million debt Canoo owes to a financial firm&#8230; conveniently run by Aquila himself. Canoo filed for Chapter 7 liquidation just six weeks ago. Government contracts with NASA and the Department of Defense bore little fruit. The startup has roughly $145 million in assets but $175 million in liabilities. Now, other buyers can still throw their hats in the ring before March 28.
<h2 class="wp-block-heading">Notes From The Block</h2>
So much for the wave of M&amp;A dealmakers expected with Trump&#8217;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates">return to the White House</a>. 
They banked on <a href="https://in.benzinga.com/news/25/02/44045159/trumps-plan-to-rein-in-regulators-could-erode-market-trust-says-2-3-trillion-asset-manager">looser regulations</a> and a more <a href="https://www.benzinga.com/25/03/44197558/whats-moving-markets-friday">vibrant stock market</a>. So far, neither scenario has come to fruition. According to Dealogic, U.S.-based M&amp;A volume is down about 29% compared to this timeframe in 2024. 
Consider the Federal Trade Commission&#8217;s (FTC) latest move. The agency, with a Trump appointee at the helm, is throwing a wrench into a private equity firm's plan to acquire Surmodics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), a company that specializes in drug delivery and in vitro diagnostic technologies.
The buyer, GTCR, already owns Biocoat, a Surmodics rival. Owning both would give them over 50% market control and the ability to squash competition. And the cost of the tech would indeed hurt the consumer. Since it's unlikely a new competitor would rise to challenge the dynamic duo of Biocoat and Surmodics, the FTC has taken the matter to court in the Northern District of Illinois.
For those surprised that the Trump administration isn&#8217;t letting this merger slide, recall his first term when the Department of Justice blocked deals between AT&amp;T and Time Warner; Sinclair and Tribune Media; Broadcom and Qualcomm as well as DraftKings and FanDuel.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/03/44110974/halle-berry-launches-a-new-business-venture-succeeds-with-netflix-and-doubles-down-on-her-luxury-malibu-home">Halle Berry Launches A New Business Venture, Succeeds With Netflix, And Doubles Down On Her Luxury Malibu Home</a></li>
</ul>
For last week&#8217;s edition of <a href="https://www.benzinga.com/news/asset-sales/25/02/43897289/deal-dispatch-hooters-plans-restructuring-prada-in-talks-to-acquire-versace">Deal Dispatch, click here</a>.

Asset Sales

ALGM

CSAN

Deal Dispatch: Clock Ticks On TikTok, Raizen Explores Asset Sale, Investors Urge Walgreens To Go Private

Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading lower in the premarket session on Friday.</a>
The firm&#8217;s stock dipped following news that the U.S. Federal Trade Commission will challenge the proposed acquisition by funds <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44183928/surmodics-issues-statement-on-u-s-federal-trade-commission-challenge-to-proposed-acquisition-of-su" rel="noreferrer noopener">affiliated with private equity firm GTCR LLC.</a>
GTCR has an equity investment in Biocoat Inc., a medical coatings manufacturer, which raised concerns for the FTC.
&#8220;The FTC charges that private equity firm GTCR's proposed acquisition of Surmodics would create a combined company controlling more than 50% of the market for outsourced hydrophilic coatings. These coatings are often used by medical device manufacturers and are applied to lifesaving medical devices such as catheters and guidewires,&#8221; the regulatory body said in a <a href="https://www.ftc.gov/news-events/news/press-releases/2025/03/ftc-challenges-medical-device-coatings-deal">release</a>.
The FTC's complaint argues that making hydrophilic coatings requires specialized expertise and significant investment and many OEMs prefer outsourcing to established companies like Biocoat and Surmodics.
After the merger, it's unlikely a new competitor could challenge GTCR and Surmodics.
In response to the FTC&#8217;s announcement, Surmodics issued a statement expressing its disagreement with the agency&#8217;s decision.
The company emphasized its commitment to completing the merger and remains confident in the deal&#8217;s potential to benefit all stakeholders, including shareholders, customers and patients.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44186784/copt-defense-properties-faces-risks-analyst-sees-uncertainty-in-leasing-process-amid-budget-cut-risks" rel="noreferrer noopener">COPT Defense Properties Faces Risks: Analyst Sees Uncertainty In Leasing Process Amid Budget Cut Risks</a>
The FTC&#8217;s complaint particularly states that GTCR's acquisition of Surmodics would raise market concentration in the hydrophilic coatings sector, which already has few competitors, violating the 2023 Merger Guidelines.
However, Surmodics said it has worked closely with the FTC for months to secure regulatory approval and voiced disappointment over the agency&#8217;s move to initiate litigation.
The company asserts that the merger is &#8220;pro-competitive&#8221; and says intends to vigorously defend the case in court.
Surmodics entered into a definitive <a href="https://www.benzinga.com/m-a/24/05/39066034/why-is-medical-coating-specialist-surmodics-trading-higher-on-wednesday">merger agreement with GTCR on May 29, 2024.</a>
Under the terms of the deal, GTCR will acquire all outstanding shares of Surmodics for $43.00 per share, resulting in an equity valuation of approximately $627 million.
The transaction is expected to be financed through a combination of equity and debt financing from GTCR.
If completed, Surmodics will become a privately held entity and its shares will no longer be listed on the Nasdaq Global Select Market. Shareholders approved the merger on August 13, 2024.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, SRDX stock has lost over 1.76% in the past year.
Price Action: SRDX shares are trading lower by 4.76% to $28.21 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44146094/wall-street-awaits-trumps-tariff-decision-digests-mixed-economic-data-whats-driving-markets-wednesday" target="_blank" rel="noreferrer noopener">Wall Street Awaits Trump&#8217;s Tariff Decision, Digests Mixed Economic Data: What&#8217;s Driving Markets Wednesday?</a></li>
</ul>
Photo: Shutterstock

Equities

Markets

Movers

Why Surmodics Stock Is Falling On Friday

Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission's ("FTC" or the "Agency") announcement that it will challenge the proposed acquisition of Surmodics (the "Merger") by funds affiliated with GTCR LLC ("GTCR"), which have an equity investment in Biocoat Inc., a maker of medical coatings:
"Surmodics respectfully disagrees with the FTC's decision and remains committed to completing the Merger. Surmodics remains confident in both its rationale for the Merger and the value it will bring to all stakeholders, including shareholders, customers and patients. We have worked constructively with the FTC over the last several months to secure regulatory approval for the Merger and are disappointed by its decision to initiate litigation, as the Merger is pro-competitive."
Surmodics intends to vigorously defend this case in court in order to complete the Merger.
Additional Information About the Pending Acquisition of Surmodics by funds affiliated with GTCR
On May 29, 2024, Surmodics announced it had entered into a definitive merger agreement to be acquired by funds affiliated with GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology. Under the terms of the merger agreement, an affiliate of GTCR will acquire all outstanding shares of Surmodics. Surmodics shareholders will receive $43.00 per share in cash, for a total equity valuation of approximately $627 million. The transaction will be financed through a combination of committed equity from funds affiliated with GTCR and committed debt financing. Upon completion of the transaction, Surmodics will be a privately held company and its common stock will no longer be listed on The Nasdaq Global Select Market.
The Merger was approved by Surmodics' shareholders at a special meeting held on August 13, 2024.

Government

Regulations

Surmodics Vows to Fight FTC Lawsuit Blocking $627M Acquisition by GTCR

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Radiopharm Theranostics ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>)</h3>
<ul>
<li>On Jan. 10, Radiopharm Theranostics announced it will execute a private placement and will raise $5 million in proceeds. The company' stock fell around 11% over the past five days and has a <a href="https://www.benzinga.com/quote/RADX">52-week low of $3.71</a>.</li>
<li>RSI Value: 27.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>RADX Price Action: Shares of RADX closed at $4.40 on Wednesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020625&amp;t=be2bearmibe3na1">RADX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="888" height="823" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043706/image-50.png" alt="" class="wp-image-768930" style="width:479px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043706/image-50.png 888w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043706/image-50-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043706/image-50-768x712.png 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
<h3 class="wp-block-heading">Surmodics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>)</h3>
<ul>
<li>On Feb. 3, Surmodics reported successful early clinical use of Pounce XL Thrombectomy System for non-surgical clot removal in iliac and femoral arteries. The company's stock fell around 15% over the past month and <a href="https://www.benzinga.com/quote/SRDX">has a 52-week low</a> of $25.21.</li>
<li>RSI Value: 29.9</li>
<li>SRDX Price Action: Shares of Surmodics gained 0.7% to close at $33.85 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020625&amp;t=be2bearmibe3na1">SRDX stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043723/image-2-9.png" alt="" class="wp-image-768931" style="width:598px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043723/image-2-9.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043723/image-2-9-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043723/image-2-9-768x697.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<h3 class="wp-block-heading">Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</h3>
<ul>
<li>On Feb. 4, Merck &amp; Co reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, sales increased 9%. Merck reported adjusted EPS of $1.72, up from $0.03 a year ago and beating the consensus of $1.62. Lower charges for business development transactions and operational strength primarily drove the increase. The company's stock fell around 10% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/MRK">low of $87.33</a>.</li>
<li>RSI Value: 28.4</li>
<li>MRK Price Action: Shares of Merck fell 1.2% to close at $89.67 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020625&amp;t=be2bearmibe3na1">MRK shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="882" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043825/image-51.png" alt="" class="wp-image-768933" style="width:525px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043825/image-51.png 882w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043825/image-51-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06043825/image-51-768x725.png 768w" sizes="(max-width: 882px) 100vw, 882px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43492050/top-3-financial-stocks-that-may-rocket-higher-this-quarter">Top 3 Financial Stocks That May Rocket Higher This Quarter</a></li>
</ul>

Long Ideas

Pre-Market Outlook

Trading Ideas

RADX

Top 3 Health Care Stocks You'll Regret Missing This Month

With the addition of the Pounce&#x2122; XL Thrombectomy System, indicated for use in 5.5–10 mm peripheral arteries, the Pounce&#x2122; Thrombectomy Platform can now rapidly remove acute or chronic clot throughout the lower extremity without aspiration, thrombolysis, or capital equipment.

Surmodics Reports Successful Early Clinical Use Of Pounce XL Thrombectomy System For Non-Surgical Clot Removal In Iliac And Femoral Arteries

Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful early clinical use of its Pounce&#x2122; XL Thrombectomy System. The Pounce XL Thrombectomy System received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2024, and is currently in limited market release (LMR), with full commercial launch planned following completion of the LMR.
Surmodics Pounce Thrombectomy systems are intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature. The new Pounce XL Thrombectomy System is indicated for use in vessels ranging from 5.5–10 mm in diameter, sizes typical of iliac and femoral arteries. The Pounce XL System complements the Pounce and Pounce LP Thrombectomy Systems, which are indicated for 3.5–6 mm and 2–4 mm vessels, respectively.

Surmodics Expands Thrombectomy Line, FDA-Cleared Pounce XL Thrombectomy System Targets Larger Arteries, Full Launch Coming Soon

Surmodics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) released its Q1 earnings on Thursday, January 30, 2025 at 07:00 AM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Surmodics beat estimated earnings by 67.0%, reporting an EPS of $-0.04 versus an estimate of $-0.12.
Revenue was down $630 thousand from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company beat on EPS by $0.16, leading to a 0.0% increase share price change the next day.
Here's a look at Surmodics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.29</td>
<td>-0.33</td>
<td>-0.32</td>
<td>-0.3</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.13</td>
<td>-0.27</td>
<td>0.07</td>
<td>0</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>30.39M</td>
<td>30.01M</td>
<td>28.84M</td>
<td>29.64M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>33.23M</td>
<td>30.34M</td>
<td>31.96M</td>
<td>30.55M</td>
</tr>
</tbody>
</table>

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Surmodics <a href="https://www.benzinga.com/quote/SRDX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Surmodics Earnings Analysis: Q1 Recap

CORRECTION: Surmodics reported Q4 financial results on Nov. 6

Press Releases

Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter

Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System

Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries

Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR

Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

Comments

Surmodics

ニュース

最新ニュース Surmodics (NASDAQ:SRDX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル